This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Consolidated Q2 FY27 revenue rises 32%, profit after tax jumps 168%
AKUMS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.0 pts more than Nifty Microcap 250 and 3.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Consolidated Q2 ended 30 September 2026: revenue from operations was ₹13,423.87 million, up 31.9% year on year from ₹10,175.30 million; profit after tax was ₹1,145.65 million, up 168.3% from ₹426.96 million. Margin before interest, tax, depreciation and amortisation rose to 14.5% from 9.3%. Consolidated half-year: revenue from operations ₹25,090.16 million; profit after tax ₹2,155.43 million. Unmodified review flagged a ₹1,560.18 million tax demand under appeal.
Strong sales and profit growth and a wider operating margin should support the stock, but the appealed tax demand creates material downside risk.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹1,342 Cr | ₹1,018 Cr | +31.9% |
| Operating profit | ₹125.8 Cr | ₹33.31 Cr | +277.8% |
| Profit after tax | ₹114.6 Cr | ₹42.70 Cr | +168.3% |
| EBITDA margin | 14.5% | 9.3% | +5.2 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.